G2E3 CRISPR Activation Plasmid (h): sc-405720-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- G2E3 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- G2E3 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by G2E3 CRISPR Activation Plasmid (h) and G2E3 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the G2E3 transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
G2E3 CRISPR Activation Plasmid (h) | sc-405720-ACT | 20 µg | $397.00 |
Human G2E3 encodes a RING-type E3 ubiquitin-protein ligase implicated in ubiquitin-dependent proteostasis and stress-responsive cell cycle control. By promoting selective ubiquitination of regulatory proteins, G2E3 is positioned to influence DNA damage signaling, checkpoint progression, and apoptosis-related processes that shape cellular survival under genotoxic or replication stress. Altered regulation of ubiquitin ligase networks that include G2E3 has been linked to genome instability phenotypes and dysregulated proliferation programs observed across disease-relevant contexts. As a result, G2E3 is frequently studied for its contribution to pathway crosstalk between ubiquitin signaling, cell cycle dynamics, and transcriptional responses to cellular stress.
G2E3 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous G2E3 expression without altering the underlying DNA sequence.
G2E3 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the G2E3 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the G2E3 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous G2E3 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native G2E3 locus and enabling the study of G2E3-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of G2E3 pathway restoration in tumor cells with silenced or reduced G2E3 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.